Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized by unknown
ACUTE REJECTION OF MURINE BONE MARROW
ALLOGRAFTS BY NATURAL KILLER CELLS AND T CELLS
Differences in Kinetics and Target Antigens Recognized
BY WILLIAM J. MURPHY, VINAY KUMAR, AND MICHAEL BENNETT
From the Department ofPathologyand Graduate Program in Immunology, University ofTexas
Health Science Center at Dallas, Dallas, Texas 75235
The nature of the effector mechanisms and target antigens involved in the
rejectionofbone marrow allografts has been controversial. This has mainly been
due to differences in the experimental model systems and the times used for
examining rejection. Acute rejection of bone marrow allografts is believed to
occur through the recognition of Hemopoietic histocompatibility (Hh)' deter-
minants present in incompatible stem cells (1). H-2-homozygous bone marrow
cells (BMC) are rejected, whereas stem cells from H-2-heterozygous donors are
not (2). It was postulated that Hh determinants are recessively inherited and
therefore not expressed on H-2 heterozygous cells. The rejection of certain
parental strain BMC by their F, hybrids (hybrid resistance) is consistent with the
idea that Hh antigens are not inherited codominantly (3). The most widely
investigated Hh antigens involved in marrow graft rejection, Hh-1 antigens, are
coded for by genes within the H-2 complex. Recent mapping studies place the
Hh-1 locus between H-2S and H-2D (4), suggesting that Hh-1 determinants are
probably not class I antigens. However, some studies have demonstrated that H-
2-heterozygous marrow grafts, which are expected to be Hh-1-, can be resisted
by lethally irradiated mice under certain experimental conditions (5, 6). This
would suggest that determinants other than Hh-I (i.e. class I MHC antigens)
may play a role in the rejection of marrow grafts.
Natural killer (NK) cells mediate specific marrow allograft rejection in the
absence of functional Tor B cells ('7). NK cells are responsible for the phenom-
enon of hybrid resistance to parental marrow grafts (3, 8). Although NK cells
have been implicated as anti-Hh effector cells, it is generally believed that NK
cells are a functionally defined population of nonspecific killer cells that would
be unlikely to specifically recognize incompatible stem cells. Therefore, another
theory toexplain the mechanism ofNK cell-mediated marrow allograftrejection
has been proposed. When an NK cell encounters an allogeneic stem cell, failure
to recognize self MHC determinants on the stem cell results in the destruction
of that cell (9). Allogeneic marrow grafts would then be rejected due to a lack
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of self MHC determinants on the cells rather than due to the presence of
allogeneic determinants.
While NK cells have been demonstrated to be effector cells in murine marrow
graft rejection, proof that NK cells can mediate marrow allograft rejection in
other species is lacking. In addition, evidence that radioresistant T cells can
respond toalloantigens is mounting (6, 10, 11). Recent studies have demonstrated
that lymphocytescan be sensitized after lethal irradiation and cause the rejection
of skin allografts in rats (12). Studies with primates and humans have also
implicated a role for Tcells in the rejection ofbone marrow transplants (13, 14).
In experiments reported here we have performed a systematic analysis of the
potential effector mechanisms responsible for the acute rejection of marrow
allografts in lethally irradiated mice. We observed that both NK cells and T cells
can be the effectors mediating the acute rejection of bone marrow allografts
after lethal irradiation. However, they differ with respect to the target antigens
recognized and the kinetics ofthe rejection response.
Materials and Methods
Mice.
￿
C57BL/6J (B6), DBA/2J, BALB/cJ, (C3H x C57BL/6)F, (C3B6F1), (C3H x
DBA/2)F, (C3D2F1), C.B-17 scid/scid (SCID), and C.B-17 +/+ mice were bred in our
own colony at the University of Texas Health Science Center. C.B-17 scid and C.B-17
+/+ mice were kept in specific pathogen-free conditions until use. BALB/c nu/nu (nude)
and BALB/c +/+ (euthymic) mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). Mice were 8-16 wk old when used. Before irradiation, mice were given
acid water (pH 2.5) and neomycin sulfate (Biosol liquid ; Upjohn Co., Kalamazoo, MI), 1
ml in 500 ml tap water.
Irradiation.
￿
Recipient mice were exposed to 450-850 cGy of "'Cs gamma radiation
at a dose rate of 85.5 cGy/min. The exposure doses were: SCID mice, 450 cGy; BALB/c
nu/nu, BALB/c +/+, and C.B-17 +/+ mice, 700 cGy; DBA/2 and B6 mice, 800 cGy; and
C3B6FI and C3D2F1 mice, 850 cGy.
Pretreatment of Mice.
￿
The anti-NK1 .1 mAb (PK136) reagent was the generous gift of
Dr. G. Koo (Merck, Sharpe, and Dohme, Inc., Rahway, NJ). PK136 in ascites form (200
kg) was injected intraperitoneally 2 d before BMC transfer (15). The anti-Lyt-2 mAb
(HO-2.2) was a gift from Delanie Cassell (University of Texas Health Science Center).
HO-2.2, in ascites form, was injected (100 ul) intraperitoneally at daily intervals starting
3 d before BMC transfer and ending 1 d after BMC transfer. In one experiment, mice
were injected with 120rugpoly(I:C) intraperitoneally on the dayofirradiation andmarrow
cell transfer.
Immunization Protocol.
￿
Spleen cell (SC) and BMC were harvested from donor mice
and suspensions of cells (3:1 SC/BMC) were exposed to 900 cGy. 10' cells were injected
together with the original BMC innoculum intravenously into the lethally irradiated
recipients.
Assayfor Marrow Cell Proliferation.
￿
The assay for the proliferation of grafted hemo-
poietic cellsin lethally irradiated mice hasbeen describedpreviously (16).Briefly, recipient
mice are lethally irradiated and infused with 1-4 x 106 BMC into a lateral tail vein . The
proliferation of donor cells in the spleens of the recipient mice was measured 4-8 d later
by measuringthe splenicincorporation of 5-"'I-iodo-2'-deoxyuridine ("'lUdR),a specific
DNA precursor and thymidine analogue. Each mouse was injected with 10' M fluoro-
deoxyuridine intraperitoneally to inhibit endogenous thymidylate synthetase . 1 h later
each mouse was injected intraperitoneally with 0.5 /Ci "'IUdR (Amersham Corp.,
Arlington Heights, IL). 4 h after injection of isotope, the animals were sacrificed and
their spleens were removed. The spleens were soaked in 70% ethanol for 2 d to elute
non-DNA "'I, and the ...I radioactivity retained was measured in a well-type gamma
counter. The data are presentedas the geometric means(with a range of 95% confidenceMURPHY ET AL.
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TABLE I
Acute Rejection ofH-2-Heterozygous and -Homozygous Marrow Allografts by Lethally
Irradiated SCID, Nude, and +/+ Recipients
SCID = C.B-17 scid/scid; +/+ = C.B17 +/+; nude = BALB/c nu/nu. All recipients in Exp. 1 were
injected with poly(I:C) at the time of cell transfer.
* Geometric mean value significantly (p < 0.05) lower than syngeneic controls.
limits) of percentage of injected '25IUdR incorporated into the spleens of groups of five
to eight mice. Irradiated recipients syngeneic with the BMC donor were used to assess
the growth potential of the grafted BMC (syngeneic controls). Lethally irradiated mice
not injected with viable BMC served as radiation controls. Both parametric and nonpar-
ametric statistical analyses were performed to determine if the geometric values ofvarious
groups differed significantly (p < 0.05) (17). The inoculum sizes used for a given time
were chosen to ensure that the isotope uptake values were on the exponential part of the
curve relating numbers of BMC grafted to percent splenic 115IUdR uptake (16).
Results
Differential Rejection of H-2-Homozygous and -Heterozygous Allogeneic BMC
Grafts. Both C.B-17 scid/scid (SCID) and BALB/c nu/nu (nude) mice are
capable of rejecting H-2-homozygous allogeneic BMC grafts (7, 18). SCID mice
lack both functional B cells and T cells due to a defect in immune receptor gene
rearrangement (19). SCID mice completely lack any T cell function (e.g. will not
reject skin allografts) yet display normal INK activity (20). This knowledge allowed
us to determine whether or not Hh-1 antigens are recognized during rejection,
or if the self-nonself hypothesis is correct; e.g., that INK cells lyse or inactivate
those potential target cells that do not share H-2 determinants with the NK cells.
We therefore challenged lethally irradiated C.B-17 +/+ (+/+), BALB/c nu/nu
(nude), and C.B-17 scid/scid (SCID) mice (all H-2d), with H-2-homozygous B6
(H-2b, Hh-l b
) or H-2-heterozygous C3B6F1 (H-2'`/H-2b, Hh-1"°") BMC grafts.
Splenic '25IUdR uptake was measured 4 or 5 d after BMC transfer. In Exp. 1,
Table I, prospective recipient mice were injected with poly(I:C) to boost NK cell
function and marrow allograft reactivity (7). Both nude and +/+ hosts resisted
Exp.
Marrow
Strain
donor
H-2
Cells
grafted
Recipient
Strain H-2
Dayof
assay
Splenic
Geo-
metric
mean
...1UdR uptake
95%
Confidence
limits
x 106
1 B6 b/b 2.5 B6 b/b 4 0.15 0.10-0.23
B6 b/b 2.5 +/+ d/d 4 0.03 0.01-0.06*
B6 b/b 2.5 Nude d/d 4 0.03 0.01-0.08*
2 B6 b/b 3.2 B6 b/b 5 0.43 0.28-0.66
B6 b/b 3.2 +/+ d/d 5 0.30 0.15-0.60
B6 b/b 7.5 +/+ d/d 5 0.83 0.39-1.75
B6 b/b 7.5 SCID d/d 5 0.11 0.02-0.49*
C3B6F1 k/b 2.5 C3B6F1 k/b 5 1.01 0.70-1.41
C3B6F1 k/b 2.5 +/+ d/d 5 1.15 1.00-1.31
C3B6F1 k/b 2.5 SCID d/d 5 0.81 0.74-0.90
C3B6F1 k/b 2.5 Nude d/d 5 0.76 0.37-1.531502
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TABLE II
Kinetics ofRejection ofH-2-Heterozygous Allogeneic BMC by Immunized Hosts
SCID,+/+, and nude areas definedin TableI. Allrecipients in Exp. 1 were injected with poly(I:C)
at the time of cell transfer.
* Inoculum size chosen such that splenic IUdR uptake values would fall on exponential portion of
curve relating uptake with numbers of BMC grafted (16).
t Geometric mean value significantly (p < 0.05) lower than syngeneic controls.
§ Mice received 10' irradiated C3B6F1 (Exp. 1 and2) or C3D2F1 (Exp. 3) SC andBMC intravenously
at time of cell transfer of viable BMC.
the growth of B6 BMC. In Exp. 2, no poly(I:C) was used. The +/+ mice failed
to resist 3.2 x 106 B6 BMC at this time, presumably because they are relatively
poor responders to B6 (Hh-lb) BMC grafts (1). However SCID mice resisted
grafts ofas much as 7.5 x 106 B6 BMC. This confirms earlier observations that
SCID mice seem to display an augmented ability to reject marrow allografts as
compared with their normal +/+ counterparts (7). Totally allogeneic C3B6F1
(H-2k/H-2b, Hh-I"°") BMC were not resisted by SCID, nude, or +/+ recipient
mice (all H-2d). These results do not support the self-nonself recognition hy-
pothesis. However, they are consistent with the idea that H-2-heterozygous stem
cells are lacking in the determinants, (presumably Hh) that are needed for NK
cell-mediated marrow allograft rejection.
Immunization of Lethally Irradiated Mice to Reject H-2-Heterozygous Allogeneic
BMC. The ability to immunize lethally irradiated rats to reject skin allografts
within 7 d (12) suggested that we may be able to sensitize radioresistant Tcells
to reject murine BMC allografts. In the first experiment (Table II), lethally
irradiated C.B-17 +/+ (H-2d) mice were immunized (or not) with irradiated
C3B6F1 SC and were simultaneously challenged with grafts of viable C3B6F1
Exp.
Marrow
Strain
donor
H-2
Cells
grafted*
Recipient
Strain H-2
Day of
assay
Splenic
Geo-
metric
mean
1211UdR uptake
95%
Confidence
limits
X 106
la C3B6F1 k/b 2.5 C3B6F1 k/b 4 1.57 0.93-2.63
C3B6F1 k/b 2.5 SCID d/d 4 1.10 0.78-1.55
C3B6F1 k/b 2.5 +/+ d/d 4 1.03 0.18-5.69
lb C3B6F1 k/b 1 C3B6FI k/b 7 2.80 1.31-5.96
C3B6F1 k/b 1 +/+ d/d 7 0.66 0.28-1.53$
C3B6F1 k/b 1 +/+§ d/d 7 0.09 0.04-0.20$
2a C3B6F1 k/b 2.5 C3B6F1 k/b 4 0.39 0.14-1.13
C3B6F1 k/b 2.5 +/+ d/d 4 0.36 0.32-0.41
C3B6F1 k/b 2.5 +/+§ d/d 4 0.56 0.39-0.81
2b C3B6FI k/b 1 C3B6F1 k/b 7 1.05 0.48-2.28
C3B6F1 k/b 1 +/+ d/d 7 1.85 0.66-5.55
C3B6F1 k/b 1 +/+§ d/d 7 0.07 0.01-0.17T
3a C3D2F1 k/d 2.5 C3132171 k/d 4 0.52 0.22-1.22
C3D2F1 k/d 2.5 B6 b/b 4 0.54 0.37-0.79
3b C3D2F1 k/d 1 C3D2F1 k/d 7 1.23 0.42-3.56
C3D2F1 k/d 1 B6 b/b 7 0.40 0.30-0.79$
C3D2F1 k/d I B6§ b/b 7 0.09 0.05-0.191
- 0 B6 b/b 7 0.02 0.01-0.08*DONOR-HOST
C3B6F1into C3B6F1
C386F1into +/+
C3B6F1into +/+
C3B6F1 into SCID
C396F1 into SCID
C3B6F1into C3B6F1
C3B6F1into nude
C3B6F1 into nude*
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1 .0 2 .0 3 .0 4.0
0.94 (0.62-1 .42)
0.45 (0.16-1.21)
0 .06 (O.D3-0.10)*
1 .32 (0.67-2.fi0)
1 .38 (0.68-2.82)
SPLENIC IUdRUPTAKE(%)
GEOMETRIC MEAN (95% CONFIDENCE L1M1TS)
FIGURE 1 .
￿
Effect of immunization on the growth of H-2-heterozygous allogeneic C3B6F1
(H-2 k/H-26, Hh-1") marrow grafts in C.B-17 scid/scid (SCID), BALB/c nu/nu (nude), and
C.B-17 +/+ (+/+) (all H-2d) recipients. Groups of six mice were lethally irradiated and infused
with 106 viable C3B6F1 BMC with or without 10 7 irradiated C3B6F1 SC and BMC. The
splenic "5lUdR uptake assay was performed 7 d after cell transfer . *Hosts immunized with
irradiated cells. *See Table 11 .
(H-2k/H-2b , Hh-lnul ) BMC. Proliferation of the donor-derived BMC was meas-
ured 4 or 7 d after cell transfer . Only 106 BMC were grafted for the 7-d assay
to prevent the isotope uptake values from falling off the exponential part of the
dose-response curve . No resistance to grafted H-2 heterozygous C3B6F1 BMC
was detected on day 4 . In contrast, the immunized mice strongly resisted growth
ofC3B6F1 BMC by day 7 (Table 11, Exp. Ib) . By day 7, even the unimmunized
mice showed some resistance to engraftment . In the second experiment, the
immunized C.B-17 +/+ hosts rejected C3B6F1 BMC by day 7, but not by day 4
(Table II, Exp . 2) . In a third experiment, using a different strain combination,
B6 (H-2b ) hosts immunized with C3D2F1 irradiated cells were able to reject
C3D2F1 (H-2k/H-2d , Hh-In"') BMC by day 7 (Table II, Exp . 3) . The kinetics of
rejection suggest that the resistance toBMC grafts detected in the first 4 or 5 d
after irradiation is mediated primarily by NK cells, but that T cells can certainly
function by day 7 .
Inability to Sensitize SCID or Nude Mice to Reject H-2-Heterozygous (Hh-1
nu11)
Allogeneic BMC. The preceding data suggest that host T cells can be sensitized
to H-2 alloantigens even after lethal total-body irradiation . If that is true, one
should not be able to immunize SCID or nude mice, which lack T cell function .
Therefore, C.B-17 +/+, SCID and nude (all H-2d) mice were irradiated and
infused with viable C3B6F1 BMC (H-2k/H-2b , Hh-1"u l), and some hosts were
simultaneously injected with irradiated C3B6F1 BMC and SC . Growth of the
viable BMC was assessed 7 d after cell transfer . The +/+ mice, as before, rejected
the H-2 heterozygous allogeneic BMC if immunized (Fig . 1) . In contrast, the
SCID and nude mice failed to reject the H-2 heterozygous allogeneic BMC even
after immunization .
Surface Markers of the Effector Cells that Reject H-2-Homozygous vs . H-2-Hetero-1504 REJECTION OF BONE MARROW ALLOGRAFTS
DONOR-HOST
DBA/2 into Balb/c
DBA/2 into B6
DBA/2 into B6 (anti-NK1 .1)
DBA/2 into B6 (anti-Lyt-2)
C3D2F1 into C3D2F1
C3D2F1 into 86
C3D2F1 into B6 * (anti-NK1 .1)
C3D2F1 into B6 * (anti-Lyt-2)
F7-1 T-T--[ F-F
-
￿
~.1 .41 (0.95-2 .0
0.02 (0.004-0.15)T
0.59 (0.13-2 .71)
0 .01 (0.006-0.05)*
￿
Day 4 assay
0.83 (0.47-1 .46)
0.06 (0.01-0.35
0.06 (0.03-0.15
0.55 (0.26-1.15)
Day 8 assay
W W I I I ~ ~W W
SPLENIC IUdR UPTAKE (%)
GEOMETRIC MEAN (95% CONFIDENCE LIMITS)
Discussion
2 .0
8)
FIGURE 2 .
￿
Effect of antibodies directed against NK or T cells to prevent rejection of BMC
allografts . Groups ofsix B6 (H-2°) mice were irradiated and infused with inocula of 2.5 X 10 6
DBA/2(H-2d, Hh-Id)BMC or 10 6 C3D2F1 (H-2"/H-2d, H-1""")BMC. *Hosts were immunized
with irradiated (900 cGy) C3D2F1 BMC and SC . *Anti-NK-1 .1 antibodies significantly (p <
0.05) enhanced growth of DBA/2 BMC in B6 hosts on day 4, while anti-Lyt-2 antibodies
significantly (p < 0.05) enhanced growth of C3D2F1 BMC in immunized B6 hostson day 8 .
zygous Allogeneic BMC .
￿
To characterize the effector cells that reject H-2-ho-
mozygous (Hh-1 +) BMC at an early time (day 4) and the effector cells that, after
immunization, reject H-2-heterozygous (Hh-1 -) BMC later (day 8), mAb to NK
and T cell surface antigens were used . Preliminary experiments indicated that
these antibodies removed the respective cell types, as determined by flow cytom-
etry of lymphoid organs, even of unirradiated mice (data not shown) . Prospective
recipient B6 (H-2b/Hh-1b) mice were injected with anti-NK-1 .1 or with anti-Lyt-
2 reagents before irradiation and transfer of viable H-2 homozygous DBA/2 (H-
2d, Hh-l') or H-2 heterozygous C3D2F1 (H-2k/H-2d, Hh-Inu") BMC. The B6
mice challenged with C3D2F1 BMC were immunized with irradiated C3D2F1
BMC and SC at the time of transfer of viable BMC. Splenic ' 25IUdR uptake was
measured 4 d after transfer of DBA/2 BMC and 8 d after transfer of C3D2F1
BMC. The anti-NK-1 .1 but not the anti-Lyt-2 antibodies prevented the rejection
of H-2 homozygous DBA/2 BMC when growth was assessed on day 4 (Fig . 2) .
In contrast, the anti-Lyt-2 but not the anti-NK-1 .1 antibodies prevented the
rejection of H-2 heterozygous C3D2F1 BMC by the immunized B6 mice when
growth was assessed on day 8 (Fig . 2) . The data indicate that NK cells mediate
rejection of H-2 homozygous allogeneic Hh-1+BMC while radioresistant Lyt-2+
T cells mediate the rejection ofH-2 heterozygous allogeneic Hh-1 - BMC.
Model to Explain the Acute Rejection ofH-2 Allogeneic BMC Grafts .
￿
The data
presented here support the contention that two principal cell types are capable
of rejecting H-2-incompatible BMC grafts in irradiated mice (Fig . 3) . H-2-
homozygous allogeneic stem cells express both Hh-1 and H-2 antigens, while H-
2-heterozygous allogeneic stem cells express H-2 but not Hh-1 antigens . We
suggest that NK cells have receptors for Hh-1 antigens but not H-2 antigens,
and that Lyt-2+ T cells (presumably cytolytic T lymphocytes) have receptors forMURPHY ET AL .
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FIGURE 3 .
￿
Model of potential effector mechanisms capable of
mediating marrow allograft rejection after lethal irradiation .
NK cells have receptors for Hh-1 antigens that are expressed on
H-2-homozygous, but not on H-2-heterozygous, marrow stem
cells . Lyt-2 T cells recognized conventional (presumably class
1) H-2 antigens that are expressed on H-2-homozygous and H-
2-heterozygous stem cells .
H-2 antigens and not Hh-1 antigens . Furthermore, NK cells actrapidly andearly
after challenge with Hh-1+ cells, whereas T cell-mediated rejection of stem cells
occurs later. Evidence to support these ideas is as follows : (a) SCID and nude
mice, which display normal NK activity but are devoid ofT cell functions, can
reject BMC from allogeneic donors that are H-2-homozygous, but cannot reject
BMC from donors that are H-2-heterozygous, even if they are immunized (Table
I, Fig. 1) ; (b) rejection of H-2-homozygous allogeneic BMC by 4 d is mediated
by NK-1 .1 + effector cells (NK cells) and not by Lyt-2+ T cells (Fig . 2) ; (c) During
the phase of NK cell-mediated rejection, irradiated and immunized mice cannot
reject H-2-heterozygous (Hh-1""°) BMC by day 4 (Table II) ; (d) Immunization
of irradiated mice at the time of BMC transfer results in the rejection of H-2-
heterozygous allogeneic BMC by 7-8 d, which is mediated by Lyt-2+T cells and
not by NK-1 .1 + cells (Table II and Fig . 2) .
This model ofrejectionmechanismsmay be able to explain previous apparently
contradictory observations in the literature . For example, Lengerova and col-
leagues observed that F, hybrid BMC were rejected by parental-strain hosts (5),
a finding at variance with the reported lack of immunogenicity of heterozygous
stem cells (2) . Moreover, Aizawa et al . (6) observed that F, hybrid BMC prolif-
erated well for the first 5 d in parental-strain hosts, but were resisted at a later
time by Thy-1.2+ cells, presumably T cells. These findings can nowbe reconciled,
since Lengerova used a splenic colony assay performed 9-10 d after BMC
transfer, during which T cells reactive to H-2 alloantigens could have been
generated . On the other hand, Bennett (2) used a 4-d I25IUdR assay, at which
time H-2-heterozygous BMC were never rejected but H-2-homozygous marrow
allografts were, indicating that only NK cell-mediated rejection was occurring
at this time point . Our model can also be used to reconcileand examine some of
the issues currently involved with human bone marrow transplantation . The
increased incidence of rejection of HLA allogeneic marrow grafts is associated
with the detection of host-type T cells cytotoxic for donor-type cells in human
marrow transplant recipients (14), and yet children with severe combined im-
munodeficiency (SCID) may resist BMC grafts if their NK cell function is nearly
normal (21) . It appears that, depending upon the circumstance (e .g ., type of
immunosuppression regimen used for the BMC transplant procedure), both of1506
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the effector mechanisms examined with this murine model, i.e. NK and T cells,
may play a role in the clinical outcome ofhuman marrow transplant recipients.
Mechanism ofRejection ofMarrow Cells by NK Cells. NK cells can mediate BMC
graft rejection, but what is the mechanism of recognition? The ability of SCID
mice devoid ofB cellsand immunoglobulins to reject H-2 homozygous allogeneic
BMC suggests that NK cells do not have to use their Fc receptors for IgG to lyse
marrow stem cells via antibody-dependent cellular cytotoxicity (22). Recent
observations by Karre and colleagues have led to a new hypothesis for NK cell-
mediated target cell lysis, with obvious extension to rejection of BMC grafts.
The principal finding is that lymphoid tumor cells are much more susceptible to
NK cells in vitro and in vivo if they express little or no class I H-2 antigens (9,
23, 24). Moreover, teratocarcinoma cells lose sensitivity to NK cells if they
differentiate and thereby begin to express H-2 class I antigens (25, 26). Cytolytic
T lymphocytes (CTL) recognize class I antigens on target cells and lyse those
target cells that express high amounts of such antigens (27). Therefore it was
postulated that T cells use their receptors to positively recognize MHC antigens
on target cells, whereas NK cells are specifically triggered by the absence or
reduced expression of self H-2 antigens. If this hypothesis were correct, one
would expect that grafts from A X B donors into B hosts would be accepted,
since B NK cells wouldrecognize B H-2 antigenson A X Bstem cells. In contrast,
A X C marrow cells would be rejected by B hosts since B NK cells would be
triggered to kill by the absence of B H-2 antigens on the A X C BMC. The
inability ofC.B-17 +/+ mice (H-2d) to reject totally allogeneic C3B6F1 (H-2k/H-
26, Hh-1"°°) BMC within 4 d even if boosted with poly(I:C), and the inability of
B6 (H-26) mice to rapidly reject allogeneic C3D2F1 (H-2k/H-2d, Hh-1null) BMC
indicates that such self-nonself discrimination based on H-2 determinants does
not apply to the NK cell-mediated rejection of BMC grafts.
Our data support the hypothesis that Hh-1 antigens are needed for the NK
cell-mediated rejection of bone marrow allografts. This occurs, presumably,
through the use ofspecific Hh-1 receptors. Unlike most other histocompatibility
(i.e. class 1) antigens, Hh-1 antigens are not inherited codominantly (2). A
potential mechanism for the apparent recessive inheritance of Hh-1 antigens is
that trans-acting genes downregulate the expression ofHh-1 antigens (28). This
may explain why homozygosity at H-2 is required for optimal immunogenicity
ofBMC grafts. It should be noted that there is a limited polymorphism of Hh-1
antigens in the mouse, especially when compared with class I or class II antigens.
Therefore, it is conceivable that instances of NK cell-mediated rejection of
marrow grafts in humans (21) may be explained by recognition of Hh antigens,
i.e. donors heterozygous for the highly polymorphic HLA class I and II deter-
minants may still be homozygous for Hh determinants that are of limited
polymorphism.
In conclusion, the data presented suggest that NK cells can mediate early BMC
graft rejection, and only stem cells expressing Hh-1 antigens are recognized. At
a later time, radioresistant T cells can mediate acute marrow graft rejection
through the recognition of H-2 antigens, a process that is enhanced if the mice
are immunized at the time of marrow transfer. Thus both NK and T cells can
mediate acute marrow allograft rejection in lethally irradiated mice, but theyWe thank Ms. Deborah Scott for excellent secretarial assistance. We also thank Drs.
Robert Tigelaar, Jonathan Sprent, and John Hackett, Jr. for critically evaluating the
manuscript. The authors are indebted to Ms. Delanie Cassell for the anti-Lyt-2 antibodies
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differ with respect to the target antigens recognized and the kinetics of the
rejection response.
Summary
Lethally irradiated C.B-17 +/+, C.B-17 scidlscid (severe combined immuno-
deficiency, SCID, BALB/c-nu/nu (nude), and C57BL/6 (B6) mice were chal-
lenged with H-2-homozygous or H-2-heterozygous totally allogeneic bone mar-
row cell (BMC) grafts. Some of the irradiated mice were immunized simultane-
ously with large numbers of irradiated marrow and spleen cells syngeneic with
the viable BMC transferred. Irradiated SCID and nude mice, devoid of T cells
but with normal NK cell function, were able to reject H-2-homozygous BMC
grafts within 4 d. However, they were unable to reject H-2-heterozygous BMC
allografts by 7 d even if they were immunized. B6 and C.B-17 +/+ mice were
able to reject H-2 heterozygous BMC allografts by 7-8 d, but not as early as 4
d, if they were immunized. The rejection of H-2-homozygous BMC on day 4
was inhibited by administration of anti-NK-1.1 antibodies, but not by anti-Lyt-2
antibodies. Conversely, the rejection of H-2-heterozygous allogeneic BMC on
day 8 was prevented by anti-Lyt-2 but not by anti-NK-1.1 antibodies. The data
indicate that both NK cells and Lyt-2+ T cells can mediate rejection ofallogeneic
BMC acutely, even after exposure of mice to lethal doses of ionizing irradiation.
NK cells appear to recognize Hemopoietic histocompatibility (Hh) antigens on
H-2 homozygous stem cells. The inability of SCID and nude mice to reject H-2
heterozygous totally allogeneic BMC indicate that NK cells do not survey donor
marrow cells for self H-2 antigens and reject those cells that express nonself H-
2 antigens. The T cells presumably recognize conventional H-2 antigens (prob-
ably class I) under these conditions.
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